Sunday 11 October 2026 · Edition of the day

Current editionPast editions →

The Skeptic's Daily

The day's biggest stories, taken apart. For each one: what is actually established, what is only asserted, the questions worth asking — and a plausibility score for the central claim, given everything currently known.

Stories
1
Average plausibility
72%
How to read the score
It rates how well the core claim is evidenced — not how important the story is, nor whether it is good or bad news.
RegionAllGlobalAfricaNorth AmericaSouth AmericaAsia-PacificEuropeMiddle East
TopicAllPoliticsConflict & SecurityBusinessScienceHealth
01HealthAsia-Pacific

Australian advocates seek subsidised weight-loss drugs for women with PMOS

The Guardian reports a subsidy campaign while noting that GLP-1 drugs are being prescribed off-label for the condition.

Australian advocates say women with PMOS should receive subsidised weight-loss drugs, according to the Guardian. The summary says GLP-1 drugs are not specifically approved by the TGA to treat the condition. It reports that patients are receiving them off-label.

What holds up

  • ✓The item reports an advocacy demand for subsidies, not a government decision to provide them.
  • ✓The summary distinguishes off-label prescribing from specific TGA approval for treating the condition.

What doesn't yet

  • ?No clinical trial results, benefit estimates or safety data are supplied.
  • ?The extract does not identify the proposed eligibility rules, costs or a government response.

Ask before you share

  • →What evidence supports the benefits and risks for this particular condition?
  • →Which drugs and patients would the proposed subsidy cover?
  • →What assessment have regulators or subsidy decision-makers made?

Sources & original reporting

  1. [1]The Guardian · Published 9 Oct 2026 · theguardian.com